Encouragingly, the two novel types of agents showed more advantages for kidney function protection than dipeptidyl peptidase-4 inhibitor or sulfonylureas [40] and were recommended by the Kidney Disease: Improving Global Outcomes guidelines guidelines [1] and consensus report by American Diabetes Association and the European Association for the study of diabetes [41, 42] in T2DM patients with chronic kidney disease. Here, DPP4 is linked to chronic kidney disease.